Shares of Halozyme Therapeutics Inc. (NASDAQ:HALO) were up 2% during mid-day trading on Monday . The company traded as high as $10.27 and last traded at $10.18, with a volume of 379,066 shares traded. The stock had previously closed at $9.98.

A number of analysts recently issued reports on HALO shares. Jefferies Group restated a “sell” rating and issued a $6.75 price target on shares of Halozyme Therapeutics in a research report on Tuesday, May 10th. Canaccord Genuity restated a “buy” rating on shares of Halozyme Therapeutics in a research report on Tuesday, May 10th. Wells Fargo & Co. restated a “buy” rating on shares of Halozyme Therapeutics in a research report on Tuesday, May 10th. Finally, Piper Jaffray Cos. restated an “overweight” rating and issued a $15.00 price target on shares of Halozyme Therapeutics in a research report on Thursday, June 9th. One research analyst has rated the stock with a sell rating, one has given a hold rating and six have assigned a buy rating to the stock. The company currently has an average rating of “Buy” and a consensus target price of $15.68.

The company’s 50-day moving average is $9.64 and its 200 day moving average is $9.44. The stock’s market cap is $1.30 billion.

Halozyme Therapeutics (NASDAQ:HALO) last issued its quarterly earnings results on Tuesday, August 9th. The biopharmaceutical company reported ($0.21) EPS for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.27) by $0.06. The firm had revenue of $33.30 million for the quarter, compared to analysts’ expectations of $29.94 million. During the same quarter in the previous year, the firm posted $0.02 earnings per share. The firm’s revenue for the quarter was down 23.3% compared to the same quarter last year. Equities research analysts forecast that Halozyme Therapeutics Inc. will post ($0.91) EPS for the current year.

Halozyme Therapeutics, Inc is a biotechnology company focused on developing and commercializing oncology therapies. The Company operates in research, development and commercialization of enzymes segment. This segment also includes research and development, and bulk rHuPH20 manufacturing activities conducted under its collaborative agreements with third parties, and product sales of Hylenex recombinant.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.